Brief: Sensorion Met Primary Endpoint For Sens-401 Phase 2A Clinical Study

Sensorion SA

11/03/2024 06:34

March 11 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION ANNOUNCES IT HAS MET PRIMARY ENDPOINT FOR
SENS-401
PHASE 2A CLINICAL STUDY FOR RESIDUAL HEARING PRESERVATION
    * PRESENCE OF SENS-401 IN PERILYMPH IS CONFIRMED IN 100% OF
PATIENTS SAMPLED FOLLOWING COCHLEAR IMPLANTATION AT LEVELS
COMPATIBLE WITH POTENTIAL THERAPEUTIC EFFICACY

Source text for Eikon:  urn:newsml:reuters.com:*:nBwbTdxPga
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587785110;))